1
|
Xu M, Xu L. Up-Regulation of miR-26a-5p Promoted Cell Growth and Tumor Metastasis of Intracranial Malignancy Through Phosphatase and Tensin Homolog Deleted on Chromosome Ten/Phosphatidylinositol3-Kinase/Protein Kinase B Signaling Pathway. J BIOMATER TISS ENG 2023. [DOI: 10.1166/jbt.2023.3228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Objective: Intracranial malignancy has ranked the 6th and 3rd in terms of global tumor morbidity and mortality, respectively. MicroRNA (miRNA) can regulate the cell physiological process. Methods: In previous study, we explored the anti-cancer effects and mechanism of
miR-26a-5p in human glioma. MiR-26a-5p expression was increased in patient with glioma. Up-regulation of miR-26a-5p promoted cell growth and tumor metastasis of human glioma through inactivation of PTEN/PI3K/Akt. Results: Down-regulation of miR-26a-5p reduced cell growth and tumor metastasis
of human glioma. Downregulation of miR-26a-5p induced PTEN protein expression, and reduced PI3K and p-Akt protein expression in human glioma. PTEN or PI3K inhibitor reduced the effects of miR-26a-5p on cell growth and tumor metastasis of human glioma. Conclusion: Our findings proved
that the cancer effect of MiR-26a-5p regulates PTEN expression and promoted cell growth of human glioma through PI3K/Akt signalling pathway.
Collapse
Affiliation(s)
- Mingtao Xu
- Department of Neurosurgery, Huhhot First Hospital, Hohhot, 010030, China
| | - Li Xu
- Department of Cardiovascular Medicine, The Affiliated People’s Hospital of Inner Mongolia Medical University, Hohhot, 010010, China
| |
Collapse
|
2
|
Guo Y, Hu H, Xu S, Xia W, Li H. Useful genes for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma. J Cancer Res Ther 2022; 18:1860-1866. [PMID: 36647943 DOI: 10.4103/jcrt.jcrt_1479_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Transarterial chemoembolization (TACE) is generally used to treat patients with hepatocellular carcinoma (HCC), a common and deadly cancer; however, its efficacy varies according to factors such as tumor volume, stage, serum alpha-fetoprotein level, and chosen feeding artery. In addition, gene-related factors have been recently suggested to be involved in the regulation and prediction of TACE outcomes. Accordingly, genes could serve as effective biomarkers to select patients who can benefit from TACE. These gene-related factors can activate signaling pathways affecting cancer cell survival while regulating the epithelial-mesenchymal transition, angiogenesis, and the tumor microenvironment, all directly associated with tumor progression, thereby affecting TACE efficacy. Moreover, this disordered gene expression is associated with poor prognosis in patients with HCC, including TACE resistance, postoperative recurrence, and metastasis. To identify the exact relationship between various genes and TACE efficacy, this review summarizes the involvement of protein-coding and non-coding genes and single nucleotide polymorphisms in TACE efficacy for predicting the efficacy of TACE; the present findings may help improve the efficacy of TACE in clinical settings.
Collapse
Affiliation(s)
- Yuan Guo
- Department of Minimal Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Hongtao Hu
- Department of Minimal Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Shijun Xu
- Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Weili Xia
- Department of Minimal Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Hailiang Li
- Department of Minimal Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| |
Collapse
|
3
|
MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. Diagnostics (Basel) 2022; 12:diagnostics12020374. [PMID: 35204465 PMCID: PMC8871153 DOI: 10.3390/diagnostics12020374] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Revised: 01/26/2022] [Accepted: 01/30/2022] [Indexed: 01/08/2023] Open
Abstract
Hepatocellular Carcinoma (HCC) is the sixth most common cancer in the world. Patients with intermediate stage (Barcelona Clinic Liver Cancer, B stage) hepatocellular carcinoma (HCC) have been able to benefit from TACE (transarterial chemoembolization) as a treatment option. MicroRNAs (miRNAs), i.e., a subclass of non-coding RNAs (ncRNAs), participate in post-transcriptional gene regulation processes and miRNA dysfunction has been associated with apoptosis resistance, cellular proliferation, tumor genesis, and progression. Only a few studies have investigated the role of miRNAs as biomarkers predicting TACE treatment response in HCC. Here, we review the studies’ characteristics from a radiological point of view, also correlating data with radiological images chosen from the cases of our institution.
Collapse
|
4
|
Xu Y, Wang T, Zeng J, Wang B, Zhou L, Yang M, Zhang L, Zhang N. Integrative Functional Genomics Implicated the Key T-/B-Cell Deficiency Regulator RAG1 in Transarterial Chemoembolization of Hepatocellular Carcinoma. Front Cell Dev Biol 2021; 9:720791. [PMID: 34646823 PMCID: PMC8502842 DOI: 10.3389/fcell.2021.720791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Accepted: 08/30/2021] [Indexed: 01/22/2023] Open
Abstract
Transarterial chemoembolization (TACE) has significantly prolonged overall survival (OS) of unresectable hepatocellular carcinoma (HCC) patients. Unfortunately, there are still a portion of patients without therapeutic responses to TACE. Although genome-wide association studies identified multiple HCC susceptibility SNPs, it is still largely unclear how genome-wide identified functional SNPs impacting gene expression contribute to the prognosis of TACE-treated HCC patients. In this study, we developed an integrative functional genomics methodology to identify gene expression-related SNPs significantly contributing to prognosis of TACE-treated HCC patients across the whole genome. Employing integration of data from expression quantitative trait locus (eQTLs) analyses of The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) as well as the 1000 Genomes project, we successfully annotated 60 gene expression-related SNPs which are associated with OS of the TCGA patients. After genotyping these 60 SNPs in our TACE cohort, we identified four SNPs (rs12574873, rs12513391, rs34597395, and rs35624901) which are significantly associated with OS of HCC patients treated with TACE. For instance, multivariate Cox proportional hazards model indicated that the rs35624901 Deletion.Deletion (Del.Del) genotype carriers had markedly prolonged OS and a 55% decreased death risk compared with individuals with the GG genotype after TACE therapy (p = 8.3 × 10–5). In support of this, the rs35624901 Del.Del genotype is correlated to higher expression of RAG1, a key T-/B-cell deficiency regulator. Our findings reported the first evidence supporting the prognostic value of four eQTL SNPs in TACE-treated HCC patients. Importantly, our data implicated that antitumor immunity might contribute to TACE efficiency for unresectable HCC patients.
Collapse
Affiliation(s)
- Yeyang Xu
- Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Teng Wang
- Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Jiajia Zeng
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Bowen Wang
- Cheeloo College of Medicine, Shandong University, Jinan, China
| | - Liqing Zhou
- Department of Radiation Oncology, Huaian No. 2 Hospital, Huaian, China
| | - Ming Yang
- Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Li Zhang
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Nasha Zhang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
5
|
Ma R, Zhao M, Zou X, Zhou J, Bai Z. MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? Oncol Lett 2021; 21:324. [PMID: 33692856 DOI: 10.3892/ol.2021.12586] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 01/27/2021] [Indexed: 12/24/2022] Open
Abstract
Hepatocellular carcinoma (HCC) is a life-threatening cancer of the digestive system, with complex pathogenesis affected by a broad spectrum of genetic and epigenetic factors. Among several factors, microRNAs (miRNAs), which are considered regulators of the post-transcriptional gene expression, play important roles in determining the malignant phenotype of HCC. In recent years, the advances in molecular genetics have resulted in the characterization of complex genetic factors and in the identification of epigenetic mechanisms of diseases. Accumulating data have suggested that miRNA polymorphisms are involved in tumorigenesis and prognosis, suggesting that the miRNAs may serve as a target for HCC with regard to pathogenesis and prognosis. In the present review, a comprehensive and detailed literature search was conducted and the role of miRNA polymorphisms in the pathogenesis and prognosis of HCC is summarized. The data proposed the use of miRNAs as targets for the diagnosis and treatment of HCC.
Collapse
Affiliation(s)
- Ruixia Ma
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.,The General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
| | - Maomao Zhao
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.,The General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
| | - Xin Zou
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.,The General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
| | - Jianye Zhou
- Key Laboratory of Stomatology of State Ethnic Affairs Commission, Northwest Minzu University, Lanzhou, Gansu 730000, P.R. China
| | - Zhongtian Bai
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.,The General Surgery Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
| |
Collapse
|
6
|
Liu Z, Wang X, Xing L, Pan Y, Huang S. The Application Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Radiofrequency Ablation Treatment for Hepatocellular Carcinoma. Cancer Biother Radiopharm 2020; 34:621-625. [PMID: 31809215 DOI: 10.1089/cbr.2019.2845] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Objective: To compare the application value of contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) in radiofrequency ablation (RFA) for treatment of hepatocellular carcinoma (HCC). Methods: A total of 112 patients with primary HCC were enrolled for the treatment of RFA and they were randomly equally divided into the CEUS group and CECT group. The gender, age, and number and maximum diameter of tumors between the two groups were compared. The median duration of follow-up was 27.0 months and the clinical outcomes were compared. Results: The average examination time period before ablation, of guiding needle insertion and of ablation in the CEUS group were significantly shorter than those in the CECT group (p < 0.05). The complete ablation rate of the CEUS group was significantly higher than that of the CECT group (86.36% vs. 73.17%, χ2 = 4.618, p = 0.032). There was no comparative difference in the incidence of complications (including fever, infection, pain, and liver injury) between the two groups (p > 0.05). The relapse rate of the CEUS group was lower and the survival rate was higher than that in the CECT group (p < 0.05). Conclusions: Compared with the CECT, the RFA for treatment of HCC guided by the CEUS shorten the time of examination and treatment. The immediate postoperative assessment can improve the overall complete ablation rate, reduce the relapse rate, and increase the survival rate, which provides insights for the clinical application.
Collapse
Affiliation(s)
- Zhen Liu
- Department of Ultrasound, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
| | - Xiaofei Wang
- Department of Ultrasound, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
| | - Lei Xing
- Department of Ultrasound, Yantai Yuhuangding Hospital, Laishan Branch, Yantai, China
| | - Yan Pan
- Department of Ultrasound, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
| | - Shengchuan Huang
- Department of Ultrasound, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
| |
Collapse
|
7
|
Zhang TQ, Su QQ, Huang XY, Yao JG, Wang C, Xia Q, Long XD, Ma Y. Micro RNA-4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy. Hepatol Commun 2018; 2:1259-1273. [PMID: 30288479 PMCID: PMC6167067 DOI: 10.1002/hep4.1245] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Accepted: 07/19/2018] [Indexed: 12/13/2022] Open
Abstract
Our previous reports have shown that microRNA-4651 is a potential early diagnostic and prognostic marker for hepatocellular carcinoma. We aimed to investigate whether microRNA-4651 modified postoperative adjuvant transarterial chemoembolization (pa-TACE) to improve the prognosis of hepatocellular carcinoma. A hospital-based retrospective study, including 302 patients with advanced-stage hepatocellular carcinoma who received tumor resection or tumor resection plus pa-TACE as an initial therapy, was conducted to assess the effects of microRNA-4651 on pa-TACE treatment. MicroRNA-4651 expression in tumor tissues was tested using the TaqMan-PCR technique. The sensitivity of tumor cells to doxorubicin (an anticancer drug used in pa-TACE procedure) was analyzed by the half-maximal inhibitory concentration (IC50). Upregulated microRNA-4651 expression in tumor tissues can improve the therapeutic response of patients with hepatocellular carcinoma on pa-TACE (hazard ratios [95% confidence intervals] = 0.32 [0.22-0.46] for death risk and 0.39 [0.28-0.56] for tumor-recurrence risk, respectively), but downregulated expression cannot. Functional analyses-displayed microRNA-4651 mimics decreased while its inhibitor increased the IC50 of tumor cells to doxorubicin (0.65 [0.61-0.69] versus 2.17 [1.98-2.37] µM). Cytochrome P450 2W1 was shown as a possible target of microRNA-4651. Additionally, dysregulation of microRNA-4651 also affected the clinical pathological features of hepatocellular carcinoma and was an independent prognostic factor for this cancer. Conclusion: These results indicate that increasing microRNA-4651 expression may be beneficial for pa-TACE in improving hepatocellular carcinoma prognosis.
Collapse
Affiliation(s)
- Tian-Qi Zhang
- Department of Pathology the Affiliated Hospital of Youjiang Medical University for Nationalities Baise China
| | - Qun-Qing Su
- Department of Pathology the Affiliated Hospital of Youjiang Medical University for Nationalities Baise China
| | - Xiao-Ying Huang
- Department of Pathology the Affiliated Hospital of Youjiang Medical University for Nationalities Baise China
| | - Jin-Guang Yao
- Department of Pathology the Affiliated Hospital of Youjiang Medical University for Nationalities Baise China.,Department of Medicine Guangxi Science and Technology University Liuzhou China
| | - Chao Wang
- Department of Medicine the Affiliated Hospital of Youjiang Medical University for Nationalities Baise China
| | - Qiang Xia
- Department of Liver Surgery Ren Ji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
| | - Xi-Dai Long
- Department of Pathology the Affiliated Hospital of Youjiang Medical University for Nationalities Baise China.,Department of Liver Surgery Ren Ji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
| | - Yun Ma
- Department of Pathology the Affiliated Tumor Hospital, Guangxi Medical University Nanning China
| |
Collapse
|
8
|
Liu Y, He A, Liu B, Zhong Y, Liao X, Yang J, Chen J, Wu J, Mei H. rs11614913 polymorphism in miRNA-196a2 and cancer risk: an updated meta-analysis. Onco Targets Ther 2018; 11:1121-1139. [PMID: 29535537 PMCID: PMC5840307 DOI: 10.2147/ott.s154211] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Several epidemiological studies have reported that polymorphisms in microRNA-196a2 (miR-196a2) were associated with various cancers. However, the results remained unverified and were inconsistent in different cancers. Therefore, we carried out an updated meta-analysis to elaborate the effects of rs11614913 polymorphism on cancer susceptibility. A total of 84 articles with 35,802 cases and 41,541 controls were included to evaluate the association between the miR-196a2 rs11614913 and cancer risk by pooled odds ratios (ORs) and 95% confidence intervals (CIs). The results showed that miR-196a2 rs11614913 polymorphism is associated with cancer susceptibility, especially in lung cancer (homozygote comparison, OR =0.840, 95% CI =0.734-0.961; recessive model, OR =0.858, 95% CI =0.771-0.955), hepatocellular carcinoma (allelic contrast, OR =0.894, 95% CI =0.800-0.998; homozygote comparison, OR =0.900, 95% CI =0.813-0.997; recessive model, OR =0.800, 95% CI =0.678-0.944), and head and neck cancer (allelic contrast, OR =1.076, 95% CI =1.006-1.152; homozygote comparison, OR =1.214, 95% CI =1.043-1.413). In addition, significant association was found among Asian populations (allele model, OR =0.847, 95% CI =0.899-0.997, P=0.038; homozygote model, OR =0.878, 95% CI =0.788-0.977, P=0.017; recessive model, OR =0.895, 95% CI =0.824-0.972, P=0.008) but not in Caucasians. The updated meta-analysis confirmed the previous results that miR-196a2 rs11614913 polymorphism may serve as a risk factor for patients with cancers.
Collapse
Affiliation(s)
- Yuhan Liu
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Anbang He
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University, National Urological Cancer Centre, Beijing, China
| | - Baoer Liu
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Yucheng Zhong
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Xinhui Liao
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Jiangeng Yang
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Jieqing Chen
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Jianting Wu
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Hongbing Mei
- Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| |
Collapse
|